Literature DB >> 24325226

Biomarkers for fatal immune response to stem cell treatment could reduce mortality.

Sophie Paczesny1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24325226      PMCID： PMC4009357          DOI： 10.2217/bmm.13.113

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


× No keyword cloud information.
  11 in total

1.  Regulation of acute graft-versus-host disease by microRNA-155.

Authors:  Parvathi Ranganathan; Catherine E A Heaphy; Stefan Costinean; Nicole Stauffer; Caroline Na; Mehdi Hamadani; Ramasamy Santhanam; Charlene Mao; Patricia A Taylor; Sukhinder Sandhu; Gang He; Arwa Shana'ah; Gerard J Nuovo; Alessandro Lagana; Luciano Cascione; Susanna Obad; Oliver Broom; Sakari Kauppinen; John C Byrd; Michael Caligiuri; Danilo Perrotti; Gregg A Hadley; Guido Marcucci; Steven M Devine; Bruce R Blazar; Carlo M Croce; Ramiro Garzon
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

3.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

4.  Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Authors:  John M Magenau; Xuemei Qin; Isao Tawara; Clare E Rogers; Carrie Kitko; Matthew Schlough; Daniel Bickley; Thomas M Braun; Pil-Sang Jang; Kathleen P Lowler; Dawn M Jones; Sung W Choi; Pavan Reddy; Shin Mineishi; John E Levine; James L M Ferrara; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

5.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

Authors:  Kirk R Schultz; David B Miklos; Daniel Fowler; Ken Cooke; Judith Shizuru; Emmanuel Zorn; Ernst Holler; James Ferrara; Howard Shulman; Stephanie J Lee; Paul Martin; Alexandra H Filipovich; Mary E D Flowers; Daniel Weisdorf; Daniel Couriel; Peter A Lachenbruch; Barbara Mittleman; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

6.  Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100.

Authors:  Franziska Leonhardt; Sebastian Grundmann; Martin Behe; Franziska Bluhm; Rebecca A Dumont; Friederike Braun; Melpomeni Fani; Katarina Riesner; Gabriele Prinz; Anne-Kathrin Hechinger; Ulrike V Gerlach; Heide Dierbach; Olaf Penack; Annette Schmitt-Gräff; Jürgen Finke; Wolfgang A Weber; Robert Zeiser
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

Review 7.  The major histocompatibility complex: a model for understanding graft-versus-host disease.

Authors:  Effie W Petersdorf
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

8.  Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease.

Authors:  Shen Dong; Sylvie Maiella; Aliénor Xhaard; Yuanyu Pang; Lynn Wenandy; Jérome Larghero; Christophe Becavin; Arndt Benecke; Elisabetta Bianchi; Gérard Socié; Lars Rogge
Journal:  Blood       Date:  2013-07-01       Impact factor: 22.113

9.  Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.

Authors:  Ken-ichi Matsuoka; John Koreth; Haesook T Kim; Gregory Bascug; Sean McDonough; Yutaka Kawano; Kazuyuki Murase; Corey Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Sci Transl Med       Date:  2013-04-03       Impact factor: 17.956

10.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

Authors:  Mark T Vander Lugt; Thomas M Braun; Samir Hanash; Jerome Ritz; Vincent T Ho; Joseph H Antin; Qing Zhang; Chee-Hong Wong; Hong Wang; Alice Chin; Aurélie Gomez; Andrew C Harris; John E Levine; Sung W Choi; Daniel Couriel; Pavan Reddy; James L M Ferrara; Sophie Paczesny
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.